You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Elevating Outcomes and Breaking Down Barriers in Inflammatory Bowel Disease

  • Authors: Anita Afzali, MD, MPH, MHCM, FACG; Aline Charabaty Pishvaian, MD, FACG; David T. Rubin, MD, FACG
  • CME / ABIM MOC / CE Released: 11/14/2022
  • Valid for credit through: 11/14/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.25 ABIM MOC points

    Nurses - 1.25 ANCC Contact Hour(s) (1.25 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for gastroenterologists, primary care physicians, obstetricians and gynecologists, nurses, and other healthcare providers who treat patients with IBD.

The goal of this activity is for learners to be better able to employ patient-centric management strategies, including shared decision-making, in patients with IBD that also consider social determinants of health and disparities in care.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Social determinants that impact outcomes of patients with IBD
  • Have greater competence related to
    • Using treat-to-target strategies in selecting evidence-based IBD treatments
    • Evaluating symptoms of IBD with validated tools
  • Demonstrate greater confidence in their ability to
    • Incorporate shared decision-making in treatment selection


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Anita Afzali, MD, MPH, MHCM, FACG

    Professor of Clinical Medicine
    Division of Digestive Diseases
    Executive Vice Chair of Medicine
    Department of Internal Medicine
    University of Cincinnati College of Medicine
    Cincinnati, Ohio

    Disclosures

    Anita Afzali, MD, MPH, MHCM, FACG, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Bristol Myers Squibb; DiaSorin; Eli Lilly; Janssen; Pfizer; Takeda; TLL Pharmaceuticals
    Speaker or member of speakers bureau for: AbbVie; Bristol Myers Squibb; Janssen; Pfizer; Takeda
    Research funding from: AbbVie; Bristol Myers Squibb; Eli Lilly; Janssen; Pfizer; Takeda
    Other: IBDHorizons – Co-Founder and Board Member; Scrubs & Heels – Co-Founder and Board Member

  • David T. Rubin, MD, FACG

    Joseph B. Kirsner Professor in Medicine
    Chief, Section of Gastroenterology, Hepatology, and Nutrition
    Director, Digestive Diseases Center
    University of Chicago Medicine
    Chicago, Illinois

    Disclosures

    David T. Rubin, MD, FACG, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Alimentiv Inc.; Altrubio; Arena Pharmaceuticals; Aslan Pharmaceuticals; Athos Therapeutics; Bellatrix Pharmaceuticals; Boehringer Ingelheim, Ltd.; Bristol Myers Squibb; Celgene Corp/Syneos; ClostraBio; Connect BioPharma; EcoR1; Eli Lilly; Genentech/Roche; Gilead Sciences; Ironwood Pharmaceuticals; Iterative Scopes; Janssen Pharmaceuticals; Kaleido Biosciences; Materia Prima; Pfizer; Prometheus Biosciences; Reistone Biopharma; Seres Therapeutics Inc.; Takeda Pharmaceuticals; Target RWE Techlab, Inc.; Trellus Health
    Research funding from: Takeda Pharmaceuticals
    Owns stock (privately owned) in: Altrubio

  • Aline Charabaty Pishvaian, MD, FACG

    Assistant Clinical Director
    Division of Gastroenterology and Hepatology
    Johns Hopkins School of Medicine
    Clinical Director, Inflammatory Bowel Disease Center
    Johns Hopkins Sibley Memorial Hospital
    Washington, DC

    Disclosures

    Participation by Dr Charabaty Pishvaian does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

    Aline Charabaty Pishvaian, MD, FACG, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Bristol Myers Squibb; Janssen; Pfizer; Phathom; Takeda

Editor

  • Roderick Smith, MS

    Senior Medical Education Director, Medscape, LLC

    Disclosures

    Roderick Smith, MS, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.25 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Elevating Outcomes and Breaking Down Barriers in Inflammatory Bowel Disease

Authors: Anita Afzali, MD, MPH, MHCM, FACG; Aline Charabaty Pishvaian, MD, FACG; David T. Rubin, MD, FACGFaculty and Disclosures

CME / ABIM MOC / CE Released: 11/14/2022

Valid for credit through: 11/14/2023

processing....

Educational Impact Challenge

The goal of this activity is for learners to be better able to employ patient-centric management strategies, including shared decision-making, in patients with IBD that also consider social determinants of health and disparities in care.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.